Voyager Therapeutics (VYGR) Net Cash Flow Growth (3y) (2017 - 2026)
Powered by 
Analysis
Voyager Therapeutics (VYGR) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | -36.28% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 30.02% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -63.92% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 93.57% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 21.38% |
| 10 | Voyager Therapeutics | 195.27 Mn | 78.93 Mn | - | 31.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.96% |
| Mar 31, 2026 | -28.66% |
| Dec 31, 2025 | 101.99% |
| Sep 30, 2025 | -40.39% |
| Jun 30, 2025 | 16.96% |
| Mar 31, 2025 | -38.32% |
| Dec 31, 2024 | -107.30% |
| Sep 30, 2024 | 97.60% |
| Jun 30, 2024 | -1,042.12% |
| Mar 31, 2024 | 78.17% |
| Dec 31, 2023 | 27.69% |
| Sep 30, 2023 | -289.89% |
| Jun 30, 2023 | -4.64% |
| Mar 31, 2023 | 28.28% |
| Dec 31, 2022 | -14.87% |
| Sep 30, 2022 | 88.77% |
| Jun 30, 2022 | -17.26% |
| Mar 31, 2022 | -39.86% |
| Dec 31, 2021 | 8.10% |
| Sep 30, 2021 | 28.57% |